Autoria principal: Maikel Ramthun (Clínica Médica, Nefrologia e Medicina Intensiva).
Revisão: Ester Martins Ribeiro (Clínica Médica e Nefrologia).
Lafayette RA, Charu V, Glassock RJ. Expert Discussion on Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Challenges and Considerations. Adv Ther. 2025; 42(5):2003-2014.
Noris M, Remuzzi G. C3G and Ig-MPGN-treatment standard. Nephrol Dial Transplant. 2024; 39(2):202-214.
Noris M, Daina E, Remuzzi G. Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrol Dial Transplant. 2023; 38(2):283-290.
Tesar V, Hruskova Z. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. Front Immunol. 2021; 12:593288.
Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019; 95(2):281-95.
Rudnicki M. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies. Biomed Res Int. 2017; 2017:2180508.
Schena FP, Alpers CE. Membranoproliferative glomerulonephritis and cryoglobulinemic clomerulonephritis. Comprehensive Clinical Nephrology. Philadelphia: Elsevier; 2014.
Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: a new look at an old entity. N Engl J Med. 2012; 366(12):1119-31.
Bayazit AK, Noyan A, Cengiz N, et al. Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome. Clin Nephrol. 2004; 61(1):25-9.